MicroRNAs: roles in cardiovascular development and disease
- PMID: 33022373
- DOI: 10.1016/j.carpath.2020.107296
MicroRNAs: roles in cardiovascular development and disease
Abstract
Cardiovascular diseases (CVDs) comprise a group of disorders ranging from peripheral artery, coronary artery, cardiac valve, cardiac muscle, and congenital heart diseases to arrhythmias and ultimately, heart failure. For all the advances in therapeutics, CVDs are still the leading cause of mortality the world over, hence the significance of a thorough understanding of CVDs at the molecular level. Disparities in the expressions of genes and microRNAs (miRNAs) play a crucial role in the determination of the fate of cellular pathways, which ultimately affect an organism's physiology. Indeed, miRNAs serve as the regulators of gene expressions in that they perform key functions both in several important cellular pathways and in the regulation of the onset of various diseases such as CVDs. Many miRNAs are expressed in embryonic, postnatal, and adult hearts; their aberrant expression or genetic deletion is associated with abnormal cardiac cell differentiation, disruption in heart development, and cardiac dysfunction. A substantial body of evidence implicates miRNAs in CVD development and suggests them as diagnostic biomarkers and intriguing therapeutic tools. The present review provides an overview of the history, biogenesis, and processing of miRNAs, as well as their function in the development, remodeling, and diseases of the heart.
Keywords: Biomarker; Cardiovascular disease; MicroRNA; Pathogenesis; Therapeutics.
Copyright © 2020 Elsevier Inc. All rights reserved.
Similar articles
-
Crafting a Blueprint for MicroRNA in Cardiovascular Diseases (CVDs).Curr Probl Cardiol. 2023 Dec;48(12):102010. doi: 10.1016/j.cpcardiol.2023.102010. Epub 2023 Aug 5. Curr Probl Cardiol. 2023. PMID: 37544621 Review.
-
Small Molecules with Big Impacts on Cardiovascular Diseases.Biochem Genet. 2020 Jun;58(3):359-383. doi: 10.1007/s10528-020-09948-z. Epub 2020 Jan 29. Biochem Genet. 2020. PMID: 31997044 Review.
-
MicroRNA in cardiovascular biology and disease.Adv Clin Exp Med. 2017 Aug;26(5):865-874. doi: 10.17219/acem/62915. Adv Clin Exp Med. 2017. PMID: 29068585 Review.
-
MicroRNA Signature and Cardiovascular Dysfunction.J Cardiovasc Pharmacol. 2015 May;65(5):419-29. doi: 10.1097/FJC.0000000000000178. J Cardiovasc Pharmacol. 2015. PMID: 25384197 Review.
-
MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases.Curr Drug Targets. 2017;18(4):463-472. doi: 10.2174/1389450117666160301101221. Curr Drug Targets. 2017. PMID: 26926467 Review.
Cited by
-
miR-26a is a Key Therapeutic Target with Enormous Potential in the Diagnosis and Prognosis of Human Disease.Curr Med Chem. 2024;31(18):2550-2570. doi: 10.2174/0109298673271808231116075056. Curr Med Chem. 2024. PMID: 38204224 Review.
-
Inhibition of RhoA and Cdc42 by miR-133a Modulates Retinoic Acid Signalling during Early Development of Posterior Cardiac Tube Segment.Int J Mol Sci. 2022 Apr 10;23(8):4179. doi: 10.3390/ijms23084179. Int J Mol Sci. 2022. PMID: 35456995 Free PMC article.
-
A Review of Pharmacology, Toxicity and Pharmacokinetics of 2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-Glucoside.Front Pharmacol. 2022 Jan 5;12:791214. doi: 10.3389/fphar.2021.791214. eCollection 2021. Front Pharmacol. 2022. PMID: 35069206 Free PMC article. Review.
-
Differentially expressed miR-127, miR-150, and miR-145 in serum extracellular vesicles are novel diagnostic biomarkers of unstable angina.Cardiovasc Diagn Ther. 2023 Oct 31;13(5):866-878. doi: 10.21037/cdt-22-575. Epub 2023 Aug 29. Cardiovasc Diagn Ther. 2023. PMID: 37941844 Free PMC article.
-
miR-1 as a Key Epigenetic Regulator in Early Differentiation of Cardiac Sinoatrial Region.Int J Mol Sci. 2024 Jun 15;25(12):6608. doi: 10.3390/ijms25126608. Int J Mol Sci. 2024. PMID: 38928314 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
